TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: >1.00E+5nMpH: 7.0Assay Description:Briefly, the experiments were performed on an IonWorks™ HT instrument (Molecular Devices Corporation), which automatically performs electrophys...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 1.44E+3nMpH: 7.0Assay Description:Briefly, the experiments were performed on an IonWorks™ HT instrument (Molecular Devices Corporation), which automatically performs electrophys...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 5.50E+3nMpH: 7.3 T: 2°CAssay Description:Compounds of the invention were tested for inhibition of the human ether a go-go related gene (hERG) K+ channel using IonWorks patch clamp electrophy...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: >1.00E+4nMpH: 7.3 T: 2°CAssay Description:Compounds of the invention were tested for inhibition of the human ether a go-go related gene (hERG) K+ channel using IonWorks patch clamp electrophy...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 5.50E+3nMpH: 7.3 T: 2°CAssay Description:Compounds of the invention were tested for inhibition of the human ether a go-go related gene (hERG) K+ channel using IonWorks patch clamp electrophy...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: >1.00E+4nMpH: 7.3 T: 2°CAssay Description:Compounds of the invention were tested for inhibition of the human ether a go-go related gene (hERG) K+ channel using IonWorks patch clamp electrophy...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 5.50E+3nMpH: 7.3 T: 2°CAssay Description:Compounds of the invention were tested for inhibition of the human ether a go-go related gene (hERG) K+ channel using IonWorks patch clamp electrophy...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: >1.00E+4nMpH: 7.3 T: 2°CAssay Description:Compounds of the invention were tested for inhibition of the human ether a go-go related gene (hERG) K+ channel using IonWorks patch clamp electrophy...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 5.50E+3nMpH: 7.3 T: 2°CAssay Description:Compounds of the invention were tested for inhibition of the human ether a go-go related gene (hERG) K+ channel using IonWorks patch clamp electrophy...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: >1.00E+4nMpH: 7.3 T: 2°CAssay Description:Compounds of the invention were tested for inhibition of the human ether a go-go related gene (hERG) K+ channel using IonWorks patch clamp electrophy...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: >1.00E+4nMpH: 7.3 T: 2°CAssay Description:Compounds of the invention were tested for inhibition of the human ether a go-go related gene (hERG) K+ channel using IonWorks patch clamp electrophy...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 5.50E+3nMpH: 7.3 T: 2°CAssay Description:Compounds of the invention were tested for inhibition of the human ether a go-go related gene (hERG) K+ channel using IonWorks patch clamp electrophy...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 5.50E+3nMpH: 7.3 T: 2°CAssay Description:Compounds of the invention were tested for inhibition of the human ether a go-go related gene (hERG) K+ channel using IonWorks patch clamp electrophy...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 550nMpH: 7.3 T: 2°CAssay Description:Compounds of the invention were tested for inhibition of the human ether a go-go related gene (hERG) K+ channel using IonWorks patch clamp electrophy...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 550nMpH: 7.3 T: 2°CAssay Description:Compounds of the invention were tested for inhibition of the human ether a go-go related gene (hERG) K+ channel using IonWorks patch clamp electrophy...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 5.50E+3nMpH: 7.3 T: 2°CAssay Description:Compounds of the invention were tested for inhibition of the human ether a go-go related gene (hERG) K+ channel using IonWorks patch clamp electrophy...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 5.50E+3nMpH: 7.3 T: 2°CAssay Description:Compounds of the invention were tested for inhibition of the human ether a go-go related gene (hERG) K+ channel using IonWorks patch clamp electrophy...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 4.50E+3nMpH: 7.35Assay Description:The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in the grow...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 2.80E+4nMpH: 7.35Assay Description:The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in the grow...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 6.00E+3nMpH: 7.35Assay Description:The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in the grow...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 1.38E+4nMpH: 7.35Assay Description:The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in the grow...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 9.50E+3nMpH: 7.35Assay Description:The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in the grow...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 1.14E+4nMpH: 7.35Assay Description:The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in the grow...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 4.50E+3nMpH: 7.35Assay Description:The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in the grow...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 4.50E+3nMpH: 7.35Assay Description:The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in the grow...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 2.30E+4nMpH: 7.35Assay Description:The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in the grow...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: >3.00E+4nMpH: 7.35Assay Description:The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in the grow...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 1.20E+4nMpH: 7.35Assay Description:The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in the grow...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 1.30E+4nMpH: 7.35Assay Description:The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in the grow...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 3.10E+4nMpH: 7.35Assay Description:The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in the grow...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 7.00E+3nMpH: 7.35Assay Description:The assay was performed on hERG channel stably expressed in HEK293 cells. The cells were cultured at 37° C. in a humidified CO2 incubator in the grow...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 1.30E+3nMpH: 7.4 T: 2°CAssay Description:The hERG IC50 values were determined by radioligand competition experiments using membrane preparations from human embryonic kidney cells that stably...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: >1.00E+4nMpH: 7.4 T: 2°CAssay Description:The hERG IC50 values were determined by radioligand competition experiments using membrane preparations from human embryonic kidney cells that stably...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 1.30E+3nMpH: 7.4 T: 2°CAssay Description:The hERG IC50 values were determined by radioligand competition experiments using membrane preparations from human embryonic kidney cells that stably...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 2.20E+3nMpH: 7.4 T: 2°CAssay Description:The hERG IC50 values were determined by radioligand competition experiments using membrane preparations from human embryonic kidney cells that stably...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 2.40E+3nMpH: 7.4 T: 2°CAssay Description:The hERG IC50 values were determined by radioligand competition experiments using membrane preparations from human embryonic kidney cells that stably...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 3.50E+3nMpH: 7.4 T: 2°CAssay Description:The hERG IC50 values were determined by radioligand competition experiments using membrane preparations from human embryonic kidney cells that stably...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 1.50E+3nMpH: 7.4 T: 2°CAssay Description:The hERG IC50 values were determined by radioligand competition experiments using membrane preparations from human embryonic kidney cells that stably...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 2.50E+4nMpH: 7.4 T: 2°CAssay Description:The hERG IC50 values were determined by radioligand competition experiments using membrane preparations from human embryonic kidney cells that stably...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 1.10E+4nMpH: 7.4 T: 2°CAssay Description:The hERG IC50 values were determined by radioligand competition experiments using membrane preparations from human embryonic kidney cells that stably...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 26.4nMpH: 7.4 T: 2°CAssay Description:The hERG IC50 values were determined by radioligand competition experiments using membrane preparations from human embryonic kidney cells that stably...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 19.3nMpH: 7.4 T: 2°CAssay Description:The hERG IC50 values were determined by radioligand competition experiments using membrane preparations from human embryonic kidney cells that stably...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 3.04E+3nMpH: 7.4 T: 2°CAssay Description:The hERG IC50 values were determined by radioligand competition experiments using membrane preparations from human embryonic kidney cells that stably...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 1.00E+4nMpH: 7.4 T: 2°CAssay Description:The hERG IC50 values were determined by radioligand competition experiments using membrane preparations from human embryonic kidney cells that stably...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 2.00E+3nMpH: 7.4 T: 2°CAssay Description:Compounds were assessed for their ability to displace [3H]astemizole using membranes from HEK-293 cells expressing the hERG K+ channel.More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 3.00E+3nMpH: 7.4 T: 2°CAssay Description:Compounds were assessed for their ability to displace [3H]astemizole using membranes from HEK-293 cells expressing the hERG K+ channel.More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 1.00E+3nMpH: 7.4 T: 2°CAssay Description:Compounds were assessed for their ability to displace [3H]astemizole using membranes from HEK-293 cells expressing the hERG K+ channel.More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 23nMpH: 7.4 T: 2°CAssay Description:Binding affinity to the hERG K+ channel was measured by displacement of [35S]-radiolabeled MK499 in membranes derived from HEK 293 cells stably trans...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 23nMpH: 7.4 T: 2°CAssay Description:Binding affinity to the hERG K+ channel was measured by displacement of [35S]-radiolabeled MK499 in membranes derived from HEK 293 cells stably trans...More data for this Ligand-Target Pair
TargetPotassium voltage-gated channel subfamily H member 2(Homo sapiens (Human))
Novobiotic Pharmaceuticals
US Patent
Novobiotic Pharmaceuticals
US Patent
Affinity DataIC50: 2.90E+3nMpH: 7.4 T: 2°CAssay Description:Binding affinity to the hERG K+ channel was measured by displacement of [35S]-radiolabeled MK499 in membranes derived from HEK 293 cells stably trans...More data for this Ligand-Target Pair